Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase II YH-S001-04 clinical trial

被引：0

作者：

Kan, Suisui ^{[1
]}

Bai, Hai ^{[2
]}

Liu, Hui ^{[3
]}

Cui, Jie ^{[4
]}

Ke, Xiaoyan ^{[5
]}

Zhang, Huilai ^{[6
]}

Liu, Lihong ^{[7
]}

Yan, Dongmei ^{[8
]}

Jiang, Yongsheng ^{[9
]}

Zang, Aimin ^{[10
]}

Qi, Junyuan ^{[11
,12
]}

Wang, Li ^{[13
]}

Liu, Zhuogang ^{[14
]}

Xu, Bing ^{[15
]}

Zhang, Ying ^{[16
]}

Zhang, Zhihui ^{[17
]}

Zhao, Xielan ^{[18
]}

Hu, Chunhong ^{[19
]}

Yang, Shenmiao ^{[20
]}

Zhou, Hui ^{[21
]}

Shi, Jinsheng ^{[21
,22
]}

Shao, Zonghong ^{[22
,23
]}

Xiang, Ying ^{[23
,24
]}

Lin, Ningjing ^{[24
,25
]}

Zhang, Mingzhi ^{[1
]}

机构：

[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China

[2] 940 Hosp Joint Logist Support Force PLA, Dept Gastroenterol, Lanzhou, Peoples R China

[3] Beijing Hosp, Dept Hematol, Beijing, Peoples R China

[4] Gansu Prov Canc Hosp, Dept Pathol, Lanzhou, Peoples R China

[5] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China

[6] Tianjin Med Univ, Canc Inst & Hosp, Dept Lymphoma, Tianjin, Peoples R China

[7] Hebei Med Univ, Hosp 4, Hosp 4, Dept Hematol, Shijiazhuang, Peoples R China

[8] Xuzhou Med Univ, Affiliated Hosp, Dept Hematol, Xuzhou, Peoples R China

[9] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China

[10] Hebei Med Univ, Affiliate Hosp, Dept Med Oncol, Baoding, Peoples R China

[11] Chinese Acad Med Sci, Inst Hematol, Dept Lymphoma, Tianjin 300020, Peoples R China

[12] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China

[13] Jiangsu Prov Hosp, Dept Hematol, Nanjing 210029, Jiangsu, Peoples R China

[14] China Med Univ, Sheng Jing Hosp, Dept Hematol, Shenyang, Peoples R China

[15] Xiamen Univ, Affiliated Hosp 1, Dept Hematol, Xiamen, Peoples R China

[16] Guangdong Med Coll, Affiliated Hosp, Dept Oncol, Zhanjiang, Peoples R China

[17] Sichuan Canc Hosp & Inst, Dept Med Oncol, Chengdu, Peoples R China

[18] Cent South Univ, Xiangya Hosp, Dept Hematol, Changsha, Peoples R China

[19] Cent South Univ, Second Xiangya Hosp, Dept Oncol, Changsha, Peoples R China

[20] Peking Univ, Peoples Hosp, Dept Hematol, Beijing, Peoples R China

[21] Cent South Univ, Affiliated Canc Hosp Xiangya Sch Med, Affiliated Canc Hosp, Dept Lymphoma & Hematol,Xiangyi Sch Med, Changsha, Peoples R China

[22] Cangzhou Cent Hosp, Dept Oncol, Cangzhou, Peoples R China

[23] Tianjin Med Univ, Gen Hosp, Dept Hematol, Tianjin, Peoples R China

[24] Chongqing Canc Hosp, Dept Hematol & Oncol, Chongqing, Peoples R China

[25] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Lymphoma, Beijing, Peoples R China

来源：

LEUKEMIA RESEARCH | 2025年 / 149卷

关键词：

Hodgkin Lymphoma; Relapsed/Refractory; PD-1; inhibitors; Zimberelimab; Efficacy; Safety; CELL TRANSPLANTATION; ADAPTED TREATMENT; SINGLE-ARM; OPEN-LABEL; PEMBROLIZUMAB; NIVOLUMAB; MULTICENTER; SAFETY;

D O I：

10.1016/j.leukres.2024.107633

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Treating relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains challenging. This report extends the three-year follow-up period for the phase II YH-S001-04 trial, expanding upon the initial 15.8- month analysis. Methods: Zimberelimab 240 mg was administered every two weeks for two years or until disease progression or death. The endpoint was the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Results: The median follow-up was 38.0 months (3.5-42.8 months). The ORR was 91.6 % (95 % CI, 83.8-95.9). Median PFS was 23.6 months, with a longer PFS in responders (28.5 months) compared to non-responders (9.2 months) (P=0.0098). Complete responders had longer mPFS than partial responders (Not reached vs. 28.5 months, P =0.3469). Relapsed patients had improved mPFS compared to refractory cHL (23.6 vs. 10.6 months, P =0.0061). Patients with <3 lines of therapy showed longer mPFS compared to >= 3 lines (not reached vs. 23.6 months, P =0.0095). The 3-year OS rate was 94.0 % (95 % CI, 85.9-97.4). No serious adverse events with incidence >5 %. Conclusions: With encouraging data on both PFS and OS, zimberelimab demonstrates ongoing efficacy and safety in treating R/R cHL, supporting zimberelimab as an effective treatment alternative for R/R cHL (NCT03655483).

引用

页数：6

共 41 条

[41] Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial
Mai, Elias K.
Nogai, Axel
Lokhorst, Henk M.
van der Holt, Bronno
Zweegman, Sonja
Weisel, Katja C.
Croockewit, Sandra
Jauch, Anna
Hillengass, Jens
Stevens-Kroef, Marian
Raab, Marc S.
Broijl, Annemiek
Bos, Gerard M. J.
Brossart, Peter
Ypma, Paula
Hanoun, Christine
Bertsch, Uta
Hielscher, Thomas
Salwender, Hans J.
Scheid, Christoph
Goldschmidt, Hartmut
Sonneveld, Pieter
[J]. HEMASPHERE, 2024, 8 (11):

← 1 2 3 4 5 →